Jill Vanak

1.1k total citations
20 papers, 754 citations indexed

About

Jill Vanak is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Jill Vanak has authored 20 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Jill Vanak's work include Lymphoma Diagnosis and Treatment (7 papers), Multiple Myeloma Research and Treatments (6 papers) and Viral-associated cancers and disorders (5 papers). Jill Vanak is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Multiple Myeloma Research and Treatments (6 papers) and Viral-associated cancers and disorders (5 papers). Jill Vanak collaborates with scholars based in United States, Spain and Israel. Jill Vanak's co-authors include Craig H. Moskowitz, Andrew D. Zelenetz, Alison J. Moskowitz, Tarun Kewalramani, Joachim Yahalom, Linda H. Aiken, Evan Wu, Herbert L. Smith, Lesly A. Kelly and Matthew D. McHugh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Medical Care.

In The Last Decade

Jill Vanak

19 papers receiving 727 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jill Vanak United States	10	375	338	214	149	125	20	754
Mhamed Harif Morocco	16	114 0.3×	318 0.9×	48 0.2×	46 0.3×	101 0.8×	64	1.1k
Jodi Skiles United States	18	52 0.1×	347 1.0×	83 0.4×	44 0.3×	341 2.7×	53	1.1k
David Baer United States	13	135 0.4×	309 0.9×	27 0.1×	69 0.5×	115 0.9×	34	868
Paola Friedrich United States	13	66 0.2×	333 1.0×	69 0.3×	117 0.8×	44 0.4×	44	1.2k
Oreofe O. Odejide United States	18	124 0.3×	474 1.4×	41 0.2×	84 0.6×	88 0.7×	64	978
Miguel Bonilla United States	21	72 0.2×	327 1.0×	32 0.1×	60 0.4×	129 1.0×	38	1.2k
Nicola Bienz United Kingdom	10	87 0.2×	115 0.3×	22 0.1×	64 0.4×	134 1.1×	15	456
Bindee Kuriya Canada	20	122 0.3×	56 0.2×	45 0.2×	42 0.3×	168 1.3×	50	1.1k
Kim Schmit-Pokorny United States	13	188 0.5×	232 0.7×	83 0.4×	24 0.2×	253 2.0×	22	570
Federico Antillón United States	15	57 0.2×	211 0.6×	33 0.2×	75 0.5×	50 0.4×	26	858

Countries citing papers authored by Jill Vanak

Since Specialization

Citations

This map shows the geographic impact of Jill Vanak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Vanak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Vanak more than expected).

Fields of papers citing papers by Jill Vanak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Vanak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Vanak. The network helps show where Jill Vanak may publish in the future.

Co-authorship network of co-authors of Jill Vanak

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Vanak. A scholar is included among the top collaborators of Jill Vanak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Vanak. Jill Vanak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S478–S479. 1 indexed citations

Mateos, María‐Victoria, Daniel Morillo, Moshe E. Gatt, et al.. (2023). S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). HemaSphere. 7(S3). e15362d7–e15362d7. 5 indexed citations

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 41(16_suppl). 8002–8002. 58 indexed citations

Magen, Hila, Daniel Morillo, Moshe E. Gatt, et al.. (2023). P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S49–S50. 1 indexed citations

Devlin, Sean M., Jill Vanak, Heather Landau, et al.. (2016). Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplantation. 51(4). 546–552. 38 indexed citations

McHugh, Matthew D., Lesly A. Kelly, Herbert L. Smith, et al.. (2013). Lower Mortality in Magnet Hospitals. JONA The Journal of Nursing Administration. 43(10). S4–S10. 31 indexed citations

McHugh, Matthew D., Lesly A. Kelly, Herbert L. Smith, et al.. (2012). Lower Mortality in Magnet Hospitals. Medical Care. 51(5). 382–388. 197 indexed citations

Smith, Stephen D., Craig H. Moskowitz, Robert M. Dean, et al.. (2011). Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. British Journal of Haematology. 153(3). 358–363. 27 indexed citations

10.

Moskowitz, Craig H., Joachim Yahalom, Andrew D. Zelenetz, et al.. (2010). High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging. British Journal of Haematology. 148(6). 890–897. 59 indexed citations

11.

Moskowitz, Alison J., Joachim Yahalom, Tarun Kewalramani, et al.. (2010). Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 116(23). 4934–4937. 162 indexed citations

12.

Moskowitz, Alison J., Miguel‐Angel Perales, Tarun Kewalramani, et al.. (2009). Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. British Journal of Haematology. 146(2). 158–163. 108 indexed citations

13.

Small, Trudy N., Andrew D. Zelenetz, Ariela Noy, et al.. (2009). Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 15(12). 1538–1542. 28 indexed citations

14.

Moskowitz, Alison J., Paul A. Hamlin, John F. Gerecitano, et al.. (2009). Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant.. Blood. 114(22). 720–720. 15 indexed citations

15.

Moskowitz, Alison J., Stephen D. Nimer, Andrew D. Zelenetz, et al.. (2008). Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma. Blood. 112(11). 776–776. 2 indexed citations

16.

Moskowitz, Craig H., Stephen D. Nimer, Andrew D. Zelenetz, et al.. (2008). Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047. Blood. 112(11). 775–775. 4 indexed citations

17.

Tichý, M, et al.. (1990). Expression of blood group A and B antigens in gastric cancer examined by monoclonal antibodies.. PubMed. 37(4). 451–9. 1 indexed citations

18.

Vanak, Jill, et al.. (1989). Detection of blood group A antigen expression in human colon cancer using monoclonal antibodies with different specificities.. PubMed. 36(4). 479–88. 6 indexed citations

19.

Vanak, Jill, et al.. (1988). [Use of monoclonal antibodies in the detection of blood group antigens A and B in the mucosa of the large intestine].. PubMed. 127(12). 364–7. 2 indexed citations

20.

Hořejšı́, Václav, et al.. (1987). Murine Monoclonal Antibodies to Human A Erythrocytes: Differential Reactivity with N‐acetyl‐D‐galactosamine. Vox Sanguinis. 52(1-2). 125–128. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact